IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

Sep 27, 2018

Copenhagen, Denmark – September 27, 2018: IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

Other news

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Announces Appointment of Devin Smith as General Counsel

IO Biotech Provides Business Update

IO Biotech Provides Business Update